Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002693 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002693: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00002693 is a Phase 1 study that has completed, run by Mayo Clinic. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002693, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with carboplatin and topotecan in treating patients with chronic myelogenous leukemia or recurrent acute leukemia.
Interventions
- DRUG carboplatin
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-10 |
| Est. Completion | 2006-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002693
The ClinicalTrials.gov registry entry for NCT00002693 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00002693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002693 about?
NCT00002693 is a clinical study titled "Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with carboplatin and topotecan in treating ...
What is the current status of trial NCT00002693?
This trial is currently completed. It is a Phase 1 study. The study started on 1995-10. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00002693?
The interventions under investigation include: carboplatin (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002693?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.